Cerevel Therapeutics Holdings General and Administrative Expenses 2011-2026 | CERE

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Cerevel Therapeutics Holdings

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
113 M	87.6 M	58.2 M	45.8 M	-	-	-	-	15.9 M	14.5 M	15.2 M	12.6 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
113 M	12.6 M	45.3 M

Quarterly General and Administrative Expenses Cerevel Therapeutics Holdings

2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
36.2 M	-	26.1 M	22.8 M	21.4 M	-	23.7 M	20.5 M	17.5 M	-	14.4 M	13.2 M	14 M	-	10.3 M	13 M	10.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
36.2 M	10.3 M	18.7 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
Amphastar Pharmaceuticals AMPH	85.9 M	$ 21.65	-	$ 1.01 B	USA
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	45.1 M	-	-	$ 28.6 M	USA
AlloVir ALVR	11 M	-	4.14 %	$ 49.1 M	USA
I-Mab IMAB	900 M	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
Ampio Pharmaceuticals AMPE	7.08 M	-	-11.43 %	$ 502 K	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	20.6 M	-	-	$ 8.42 M	USA
Aptorum Group Limited APM	5.41 M	$ 0.9	-0.18 %	$ 6.62 M	China
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	488 M	$ 22.3	-	$ 3.7 B	USA
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Brainstorm Cell Therapeutics BCLI	5.78 M	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	106 M	-	-4.8 %	$ 255 M	USA
AIkido Pharma AIKI	23.8 M	-	1.93 %	$ 17.4 M	USA
Cara Therapeutics CARA	8.74 M	-	-3.03 %	$ 260 M	USA
CASI Pharmaceuticals CASI	23.8 M	-	-	$ 35.4 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Fennec Pharmaceuticals FENC	28.3 M	$ 6.85	-	$ 196 M	USA
ChromaDex Corporation CDXC	27.1 M	-	-0.88 %	$ 598 M	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
Galectin Therapeutics GALT	5.8 M	$ 2.37	-	$ 151 M	USA
AgeX Therapeutics AGE	11 M	-	-10.17 %	$ 12.2 K	USA
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA
Greenwich LifeSciences GLSI	3.06 M	$ 23.99	-	$ 312 M	USA
Aridis Pharmaceuticals ARDS	7.16 M	-	17.91 %	$ 11.1 M	USA
BioNTech SE BNTX	286 M	$ 102.06	-	$ 27.2 B	Germany
Checkpoint Therapeutics CKPT	20.1 M	-	-	$ 169 M	USA
Avenue Therapeutics ATXI	3.65 M	-	-52.27 %	$ 4.45 M	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
Heron Therapeutics HRTX	54.6 M	$ 1.19	-	$ 198 M	USA
Aquestive Therapeutics AQST	79.8 M	$ 4.1	-	$ 438 M	USA
Arcutis Biotherapeutics ARQT	275 M	$ 23.42	-	$ 2.98 B	USA
ImmuCell Corporation ICCC	3.2 M	$ 8.25	-	$ 74.5 M	USA
Autolus Therapeutics plc AUTL	132 M	$ 1.42	-	$ 378 M	Britain
Aptose Biosciences APTO	13.4 M	-	-45.71 %	$ 1.2 M	Canada
AstraZeneca PLC AZN	15.2 B	-	-	$ 96.9 B	Britain
AVROBIO AVRO	24 M	-	1083.1 %	$ 745 M	USA
Inventiva S.A. IVA	11.2 M	$ 5.13	-	$ 138 M	France
Can-Fite BioPharma Ltd. CANF	3.66 M	$ 2.92	-	$ 4.81 M	Israel
BeiGene, Ltd. BGNE	2.08 B	-	0.49 %	$ 251 B	Cayman-islands
Kamada Ltd. KMDA	12.6 M	$ 8.2	-	$ 260 M	Israel